Beyond Viatris: Kiran Mazumdar-Shaw Talks Next Steps For Biocon Biologics
Biocon Founder And Chairperson Discusses Integration, Pipeline And New Target Markets
As Biocon Biologics completes its integration of the biosimilars front-end business that it acquired from former partner Viatris, Biocon founder and chairperson Kiran Mazumdar-Shaw talks to Generics Bulletin about how the firm is now capturing the full value of its biosimilars, while also looking at expanding into new markets previously unserved by Viatris.
